- Home
- SMID vs PBYI Comparison
SMID vs PBYI Comparison
Compare SMID & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- PBYI
- Stock Information
- Founded
- SMID 1960
- PBYI 2010
- Country
- SMID United States
- PBYI United States
- Employees
- SMID N/A
- PBYI N/A
- Industry
- SMID Building Materials
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SMID Industrials
- PBYI Health Care
- Exchange
- SMID Nasdaq
- PBYI Nasdaq
- Market Cap
- SMID 206.7M
- PBYI 237.2M
- IPO Year
- SMID 1995
- PBYI N/A
- Fundamental
- Price
- SMID $36.14
- PBYI $5.13
- Analyst Decision
- SMID
- PBYI Strong Buy
- Analyst Count
- SMID 0
- PBYI 1
- Target Price
- SMID N/A
- PBYI $7.00
- AVG Volume (30 Days)
- SMID 11.0K
- PBYI 521.9K
- Earning Date
- SMID 08-14-2025
- PBYI 11-06-2025
- Dividend Yield
- SMID N/A
- PBYI N/A
- EPS Growth
- SMID 162.25
- PBYI 434.29
- EPS
- SMID 2.27
- PBYI 0.97
- Revenue
- SMID $90,998,000.00
- PBYI $238,062,000.00
- Revenue This Year
- SMID N/A
- PBYI N/A
- Revenue Next Year
- SMID N/A
- PBYI N/A
- P/E Ratio
- SMID $15.90
- PBYI $5.27
- Revenue Growth
- SMID 32.97
- PBYI 8.63
- 52 Week Low
- SMID $25.13
- PBYI $2.32
- 52 Week High
- SMID $51.96
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- SMID 41.00
- PBYI 60.00
- Support Level
- SMID $35.16
- PBYI $4.95
- Resistance Level
- SMID $37.25
- PBYI $5.33
- Average True Range (ATR)
- SMID 2.33
- PBYI 0.25
- MACD
- SMID -0.33
- PBYI 0.05
- Stochastic Oscillator
- SMID 24.92
- PBYI 72.49
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.